Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

Advances in Sustained-Release Agents for Post-Vitrectomy Pain and Inflammation

By: Marc C. Peden, MD; Ivan J. Suñer, MD, MBA

Webinar Credits: .5

Despite the routine use of antibiotics, corticosteroids, and nonsteroidal anti-inflammatory (NSAID) agents in postoperative ophthalmic surgical care, there remain issues with drug delivery of these agents. Ongoing education about novel corticosteroids and technologies is warranted to ensure eye care providers can deliver the best patient care possible.

All education activities identified in this education design document will be targeted to ophthalmologists and optometrists. The following categories of doctors have been identified as those with the greatest need for this educational intervention:
I. Ophthalmologists who perform ophthalmic surgery.
II. Ophthalmologists involved in the management of ocular inflammation following ophthalmic surgery.
III. Optometrists who comanage patients following cataract surgery.


Expiration Date: Thursday, September 08, 2022
Release Date: Sept 14, 2020

Learning Objectives

At the completion of this educational activity, you will be better able to:

  • Identify issues with adherence and compliance with postoperative regimens
  • Compare drug delivery options for control of inflammation after surgery
  • Interpret and explain latest available treatments available
  • Discuss reimbursement for different drug delivery options

 

Accreditation and Designation Statement

Provided by Evolve Medical Education

Accreditation Statement

Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve designates this enduring. material for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Sponsored by:

Evolve is an approved COPE Administrator.
This course is COPE approved for .5 hour of CE credit for optometrists.

COPE Course ID: 69554-PH
COPE Activity ID: TBD

 

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

 

Course Viewing Requirements

Supported Browsers:

Internet Explorer 11 for Windows

Edge (recent versions; Chromium-based) for Windows

Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux

Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:

4GB+ RAM

Recommended internet speed 5Mbps+

Faculty and Disclosures

Marc C. Peden, MD
Retina Associates of Florida
Tampa, Florida

Ivan J. Suñer, MD, MBA
Retina Associates of Florida
Tampa, Florida

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Marc C. Peden, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Grant/Research Support: Alimera, Allergan, Apellis, Genentech, Kodiak Sciences, Novartis and Roche.  Speaker’s Bureau: Genentech.

Ivan J. Suner, MD, MBA and/or spouse has had a financial agreement or affiliation during the past year with  the following commercial interests in the form of Consultant: Alimera, Genentech/Roche, Ocular Therapeutix and Regeneron Pharmaceuticals. Grant/Research Support: Alimera, Genentech/Roche, Ocular Therapeutix and Regeneron Pharmaceuticals. Speaker’s Bureau: Genentech/Roche and Regeneron Pharmaceuticals.

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.

 

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Ocular Therapeutix.

 

Pretest

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident

Video Resources

Next

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • 1. Not at all confident2. Not very confident3. Neutral4. Confident5. Extremely confident
  • AgreeNeutralDisagree
    Identify the issues surrounding patient adherence and compliance with topical medications after ocular surgery
    Discuss the role of inflammation and ocular surface disease in chronic ocular diseases commonly treated with topical medications
    Compare the drug delivery properties of novel sustained-release medications
    Interpret and explain to patients the latest available treatments and determine which option is best for each patient
    Describe how federal regulations on reimbursement affect practices as well as patients being treated for pain and inflammation associated with ophthalmic surgery
Back